The Avelle® Negative Pressure Wound Therapy System on Chronic Wounds

NCT ID: NCT05666570

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-05-18
• Study Completion Date: 2023-03-21

Brief Summary

This study seeks to demonstrate the performance of Negative Pressure Wound Therapy on chronic wounds such as diabetic foot ulcers and venous leg ulcers.

Detailed Description

This study seeks to demonstrate the performance of Negative Pressure Wound Therapy on chronic wounds such as diabetic foot ulcers and venous leg ulcers. The primary objective of the study is to demonstrate the performance and safety of Avelle Negative Pressure Wound Therapy on wound and wound fluid management when used in accordance with the instructions for use.

Participation in the study is anticipated to be two weeks. The Avelle™ NPWT System will be used for two weeks and participants will be seen for study visits during this time. Study participants will need to visit the doctor's office up to five times and, at a minimum, will be required to see the health care provider three times, dependent on the condition of the wound. Each visit is anticipated to last for approximately 45 to 60 minutes.

Conditions

Diabetic Foot Ulcer; Venous Leg Ulcer

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Avelle NPWT

Avelle Negative Pressure Wound Therapy administrated as indicated by IFU

Avelle NPWT

Intervention Type: DEVICE

Wound Management Therapy

Interventions

Avelle NPWT

Wound Management Therapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Venous insufficiency as defined by CEAP Classification of C6 or C6R or Diabetic foot ulcer
• Stalled wound/failed treatment in the opinion of the investigator. Defined as a wound that has not progressed by more than 30% in the previous 4 weeks
• 1 qualifying wound which is amenable to NPWT
• Reliable and available for follow-up
• Low to moderate exudate
• Able to tolerate negative pressure
• >18 years old at the time of consent
• Able and willing to provide informed consent

Exclusion Criteria

• Known sensitivities or allergies to components of the Avelle™ Negative Pressure Wound Therapy System
• Necrotic wounds or wounds with eschar present
• Wound is too small or too large based on wound dressing (> 1cm2 and < 100cm2)
• Wound depth >2cm
• Use of DuoDERM® gel /petroleum gel/ creams/oil-based products
• Active treatment for cancer or completed within the last 3 months
• Severe malnutrition in the opinion of the investigator
• Visible bone/tendon or exposed articular capsule
• Exposed blood vessels
• Clotting disorder
• Malignant wounds
• Systemic infection
• Untreated osteomyelitis
• Patients with HbA1c greater than 9 on Day 0 (Test to be performed within last 3 months)
• Wounds greater than 12 months old
• Previous failed NPWT within last 6 weeks on the qualifying wound
• Active Pregnancy
• Chronic Kidney Disease score of 5

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ConvaTec Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jorge Ulloa

Role: PRINCIPAL_INVESTIGATOR

Contracted independent health professional

Locations

Convatec Medical Care

Bogota, Cundinamarca, Colombia

Countries

Colombia

Other Identifiers

WC-22-432

Identifier Type: -

Identifier Source: org_study_id